

Research Evidence Sheet

SEO recommendation topic: **Topic 2 - PTSD & Trauma**

Safety, Feasibility, and Preliminary Clinical Outcomes of Psilocybin-Assisted Therapy for Veterans With Severe, Treatment-Resistant PTSD: An Open-Label Pilot Clinical Trial

Armstrong SB, Levin AW, Sepeda ND, et al. Communications Medicine. 2026;6:411.

Preliminary / Investigational

ACCESS STATUS: The complete journal article is not reproduced in this Satya business binder. Article is licensed CC BY-NC-ND 4.0. Noncommercial/no-derivatives terms make full redistribution inappropriate in this Satya business binder. Access sheet only.

Study design	Open-label pilot: psychotherapy plus two psilocybin sessions (15 mg and 25 mg) spaced 2-3 weeks apart.
Population	12 U.S. military veterans with severe, treatment-resistant PTSD.
Why it matters to this SEO topic	As of August 2026, this is directly relevant human psilocybin-PTSD evidence, but it is preliminary and far weaker than the depression/AUD evidence base.

What the study found

- The authors reported no serious adverse events and described the protocol as feasible in this small veteran sample.
- Large clinician-rated PTSD symptom reductions were reported, with high response/remission proportions at one month.
- The study is hypothesis-generating rather than confirmatory because it had no blinded control group and only 12 participants.

Important limitations / boundaries

- Open-label design, no placebo/control group, very small sample and short follow-up.
- Veterans with severe treatment-resistant PTSD are a specific population.
- Expectancy effects and intensive psychotherapy may have contributed substantially to outcomes.

How this can be used responsibly in Satya content

- The PTSD page should say psilocybin-specific PTSD research is emerging and cite this as a small 2026 pilot.
- Do not describe psilocybin as an established PTSD treatment or imply efficacy comparable to larger controlled trials in other conditions.

Important: Clinical-trial results are evidence about the study population and protocol. They do not establish that Oregon psilocybin services at Satya will reproduce the same outcomes, and they should not be presented as a guarantee of benefit.

Official source / access

[Open the official study page](#)

DOI: [10.1038/s43856-026-01767-4](#)

Binder rights note: Article is licensed CC BY-NC-ND 4.0. Noncommercial/no-derivatives terms make full redistribution inappropriate in this Satya business binder. Access sheet only.

Evidence library reviewed: August 7, 2026